AML Treatment Developments: Key Takeaways From ASH 2018

Published on

Topics include: Emerging Research

In 2018, there were more changes to the landscape of acute myeloid leukemia (AML) treatment than we have seen in the last 40 years. Watch as we discuss with Dr. Naval Daver, from MD Anderson Cancer Center, some of the clear takeaways and developments from this year’s ASH meeting and beyond. What can patients look forward to? How are different types of patients being treated? We answer some key questions. 

This is a Patient Empowerment Network program produced by Patient Power in partnership with The Leukemia & Lymphoma Society. We thank Celgene Corporation, Daiichi Sankyo, Genentech, Helsinn and Novartis for their support.

View more programs featuring and

Produced in association with and


Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Beth Probert:

So, I wanted to shift gears a little bit, Dr. Daver, and find out from you what are some of the key takeaways for AML patients and care partners from ASH. 

And I also wanted to say what I’ve heard a lot, in regard to AML is that, for almost 40 years, there was just a standard way of treating. And all of a sudden, in the very recent years or maybe year, I’m hearing that there’s so much now, new drugs and things happening. So, would you mind touching upon some of those key takeaways?

Dr. Daver:                    

Absolutely. I think, this year 2018 was clearly the year of AML. There’s just, compared to all of the other malignancies, in the last two years, there’s just been a huge amount of progress in the way of approvals. Now, what I do have to say is, although we are seeing the fruits of a lot of efforts, actually, the research in AML has been very intensive for the last 15 to 20 years. And what we’re now seeing is really the combination of a lot of those efforts. Molecular, immune analysis, which have led to these drug approvals. 

But today, really, I think, compared to even three years ago, when we did not have a number of these drugs, the whole outlook for treatment of AML has changed dramatically. So, we’ve had eight new drugs approved in a few years. And, to put it in perspective, for the 40 years before that, we actually really had almost no drug approved. There was one drug, gemtuzumab (Mylotarg), approved, but it was actually withdrawn from the market. So, when they say when it rains, it pours, that kind of really did happen, in the case of acute myeloid leukemia. But what’s really important, I think, I that there are now a number of targeted therapies towards particular mutations. 

And some of these have actually been approved, in the frontline setting. So, now, it has become very important that we don’t just treat all AMLs as one disease. In fact, that’s something we knew for about 20 years that AML is one of the most heterogenous of all malignancies. Lung cancer and AML, these are probably the two most heterogenous cancers where it’s not really this is AML, it’s different types of AML, which can have prognosis of 95 percent cure rate all the way down to 10 to 15 percent.

So, identifying these groups was very important for prognosis. And that’s something we have been doing but more important for treatment. So, for example, a mutation that is called an FLT3 mutation is very, very important because, on its own, it is associated with an adverse prognosis. These patients had high white counts, proliferative disease, and their three year or five-year survival was usually 20 to 25 percent, when we first identified this mutation in 2001. Now, there are new drugs called FLT3 inhibitors that specifically inhibit the FLT3 mutation pathway. 

And with the addition of FLT3 inhibitors, specifically a drug called midostaurin (Rydapt) that was FDA approved 1.5 years ago, plus stem cell transplant, and even more so, at the recent ASH 2018 meeting doing post stem cell transplant, FLT3 inhibitor, when we do all of these three interventions, we’re now getting up to five-year plus survival rates of 75 percent. So, this is amazing.  

The patient who was 25 percent 12 years or 13 years ago, when we first identified this mutation, could today, if appropriately treated with FLT3 inhibitor transplant and FLT3 inhibitor maintenance, could be in a 75 percent long term survivor rate. So, tripling those outcomes. And similar things are being seen for other groups. For example, APL, acute promyelocytic leukemia, is one disease where we actually are able to treat these patients without chemotherapy. So, you can give a combination of ATRA arsenic, which gives you 95 percent cure rates. 

So, the key now, and what I tell a lot of our community doctors, our fellows, other academicians is it’s not about just rushing in treatment, which has been the paradigm for 30 or 40 years, but more important, it identifies specific molecular mutations or cytogenetic changes and choose the best treatment because the impact of choosing the appropriate molecular or non-chemotherapy or antibody based treatment is, actually, much more than quick therapy. And I think that message now is going out.  

And things are improving overall.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

How Likely Is It for a Patient's Myelofibrosis or MDS to Transform Into AML?

What percentage of people with MDS or an MPN transform into AML? Our expert panel explains the signs to look for and what tests are done for patient risk assessment.


What Are the Side Effect Profiles for Modern AML Treatments?

What potential side effects can AML patients expect from powerful new therapies? Expert, Dr. Ross Levine explains.


How to Test for, Identify and Treat AML Subtypes

How many subtypes of AML are there? Are you getting the right testing done? AML expert Dr. Ross Levine joined us at ASH 2017 to discuss testing for subtypes and an individualized approach to treatment.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on September 9, 2019